In last trading session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) saw 1.03 million shares changing hands with its beta currently measuring 0.54. Company’s recent per share price level of $7.99 trading at -$0.38 or -4.54% at ring of the bell on the day assigns it a market valuation of $546.34M. That closing price of PHAT’s stock is at a discount of -146.68% from its 52-week high price of $19.71 and is indicating a premium of 24.03% from its 52-week low price of $6.07. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.92 million shares which gives us an average trading volume of 1.28 million if we extend that period to 3-months.
For Phathom Pharmaceuticals Inc (PHAT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 10 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.07 in the current quarter.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Upright in the red during last session for losing -4.54%, in the last five days PHAT remained trading in the red while hitting it’s week-highest on Wednesday, 12/18/24 when the stock touched $7.99 price level, adding 7.09% to its value on the day. Phathom Pharmaceuticals Inc’s shares saw a change of -12.49% in year-to-date performance and have moved -4.82% in past 5-day. Phathom Pharmaceuticals Inc (NASDAQ:PHAT) showed a performance of -10.12% in past 30-days. Number of shares sold short was 14.05 million shares which calculate 7.98 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 20 to the stock, which implies a rise of 60.05% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -50.19% in reaching the projected high whereas dropping to the targeted low would mean a loss of -50.19% for stock’s current value.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
Statistics highlight that Phathom Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -32.35% of value to its shares in past 6 months, showing an annual growth rate of -71.54% while that of industry is 17.30. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 7,437.52% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 25.38M for the same. And 3 analysts are in estimates of company making revenue of 28.02M in the next quarter. Company posted 682k and 1.91M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -137.06% during past 5 years.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders
Insiders are in possession of 7.73% of company’s total shares while institution are holding 110.56 percent of that, with stock having share float percentage of 119.82%. Investors also watch the number of corporate investors in a company very closely, which is 110.56% institutions for Phathom Pharmaceuticals Inc that are currently holding shares of the company. FRAZIER LIFE SCIENCES MANAGEMENT, L.P. is the top institutional holder at PHAT for having 10.11 million shares of worth $104.13 million. And as of 2024-06-30, it was holding 17.3189 of the company’s outstanding shares.
The second largest institutional holder is MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, which was holding about 7.46 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.788 of outstanding shares, having a total worth of $76.89 million.
